Education
About Us
Working with TipRanks
Follow Us
Catalyst Pharma (CPRX)
NASDAQ:CPRX
CPRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.47 - $26.16
Previous CloseN/A
Volume328.11K
Average Volume (3M)1.43M
Market Cap
$2.93B
Enterprise Value$2.12B
Total Cash (Recent Filing)$6.76M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)18.4
Beta1.18
Next Earnings
May 07, 2025EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.31
Shares Outstanding121,449,650
10 Day Avg. Volume1,787,277
30 Day Avg. Volume1,434,890
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)N/A
Price to Sales (P/S)5.98
Price to Cash Flow (P/CF)10.40
P/FCF Ratio10.40
Enterprise Value/Market Cap0.72
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.02
Enterprise Value/Ebitda9.91
Forecast
1Y Price Target
$33.83Price Target Upside40.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Catalyst Pharma News
PremiumCompany Announcements
Catalyst Pharmaceuticals Reports Record 2024 Financial ResultsPremiumCompany Announcements
Catalyst Pharmaceuticals Reports Strong Growth Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
Litigation OutcomeCatalyst is well-positioned for favorable outcomes in the unresolved litigation with Hetero and Lupin, and the Firdapse patents are expected to be upheld.
Market StrategyStrong penetration into the DMD market with a significant percentage of switches from prednisone and new enrollments from Emflaza.
Revenue GrowthCatalyst has delivered consistent double-digit year-over-year growth in Firdapse revenues.
Bears Say
Generic CompetitionFycompa sales are likely to be negatively impacted this year by generic entry in May.
Patent LitigationThe trend of historical precedent suggests that when one first filer settles or is defeated, the others often follow suit within a reasonable timeframe.
---
Ownership Overview
6.26% Insiders
17.71% Mutual Funds
16.76% Other Institutional Investors
34.93% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CPRX FAQ
What was Catalyst Pharma’s price range in the past 12 months?
Catalyst Pharma lowest stock price was $14.47 and its highest was $26.16 in the past 12 months.
What is Catalyst Pharma’s market cap?
Catalyst Pharma’s market cap is $2.93B.
When is Catalyst Pharma’s upcoming earnings report date?
Catalyst Pharma’s upcoming earnings report date is May 07, 2025 which is in 32 days.
How were Catalyst Pharma’s earnings last quarter?
Catalyst Pharma released its earnings results on Feb 26, 2025. The company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.339 by $0.101.
Is Catalyst Pharma overvalued?
According to Wall Street analysts Catalyst Pharma’s price is currently Undervalued.
Does Catalyst Pharma pay dividends?
Catalyst Pharma does not currently pay dividends.
What is Catalyst Pharma’s EPS estimate?
Catalyst Pharma’s EPS estimate is 0.34.
How many shares outstanding does Catalyst Pharma have?
Catalyst Pharma has 121,449,650 shares outstanding.
What happened to Catalyst Pharma’s price movement after its last earnings report?
Catalyst Pharma reported an EPS of $0.44 in its last earnings report, beating expectations of $0.339. Following the earnings report the stock price went up 5.248%.
Which hedge fund is a major shareholder of Catalyst Pharma?
Currently, no hedge funds are holding shares in CPRX
---
Catalyst Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.83 (40.32% Upside)
$33.83 (40.32% Upside)
Blogger Sentiment
Bullish
CPRX Sentiment 83%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 3.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.64%
12-Months-Change
Fundamentals
Return on Equity
29.38%
Trailing 12-Months
Asset Growth
81.07%
Trailing 12-Months
Company Description
Catalyst Pharma
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
---
CPRX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and successful product launches, particularly with AGAMREE and FIRDAPSE, supported by a strong financial position and favorable patent resolution. However, there are challenges with anticipated revenue decline for FYCOMPA due to patent expiry, increased SG&A expenses, and expected impacts from the Inflation Reduction Act.Read More>---
CPRX Stock 12 Month Forecast
Average Price Target
$33.83
▲(40.32% Upside)
Technical Analysis
Amgen
―
BioMarin Pharmaceutical
―
Regeneron
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering CPRX
1 Year
1 Year Success Rate
12/12 ratings generated profit
1 Year Average Return
+27.62%
reiterated a buy rating last month
Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +27.62% per trade.
---